Man Group plc Makes New $2.19 Million Investment in Kymera Therapeutics, Inc. $KYMR

Man Group plc purchased a new stake in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 19,085 shares of the company’s stock, valued at approximately $2,188,000.

A number of other institutional investors have also recently made changes to their positions in the company. BlackRock Inc. purchased a new position in Kymera Therapeutics in the 2nd quarter worth approximately $635,067,000. Baker BROS. Advisors LP boosted its stake in Kymera Therapeutics by 30.2% during the 4th quarter. Baker BROS. Advisors LP now owns 8,657,242 shares of the company’s stock valued at $673,620,000 after purchasing an additional 2,005,813 shares during the last quarter. Avoro Capital Advisors LLC increased its holdings in shares of Kymera Therapeutics by 17.7% in the 4th quarter. Avoro Capital Advisors LLC now owns 7,474,747 shares of the company’s stock worth $581,610,000 after purchasing an additional 1,124,747 shares in the last quarter. Price T Rowe Associates Inc. MD increased its holdings in shares of Kymera Therapeutics by 20.8% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 6,159,335 shares of the company’s stock worth $479,258,000 after purchasing an additional 1,061,957 shares in the last quarter. Finally, Vanguard Group Inc. raised its stake in shares of Kymera Therapeutics by 15.6% in the fourth quarter. Vanguard Group Inc. now owns 6,267,644 shares of the company’s stock worth $487,685,000 after purchasing an additional 845,922 shares during the last quarter.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on KYMR. B. Riley Financial upped their price target on Kymera Therapeutics from $117.00 to $155.00 and gave the company a “buy” rating in a report on Monday, June 29th. Oppenheimer reissued an “outperform” rating and issued a $125.00 target price on shares of Kymera Therapeutics in a research report on Wednesday, August 5th. TD Cowen raised shares of Kymera Therapeutics to a “strong-buy” rating in a report on Monday, August 24th. Guggenheim lifted their price target on shares of Kymera Therapeutics from $135.00 to $170.00 and gave the stock a “buy” rating in a research note on Monday. Finally, Wells Fargo & Company boosted their price objective on shares of Kymera Therapeutics from $116.00 to $151.00 and gave the company an “overweight” rating in a report on Thursday, August 27th. One equities research analyst has rated the stock with a Strong Buy rating, twenty have assigned a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $128.70.

Insider Buying and Selling at Kymera Therapeutics

In other news, CEO Nello Mainolfi sold 50,000 shares of the company’s stock in a transaction on Tuesday, July 7th. The stock was sold at an average price of $119.00, for a total value of $5,950,000.00. Following the completion of the sale, the chief executive officer directly owned 666,568 shares in the company, valued at $79,321,592. This represents a 6.98% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, Director Bruce Booth sold 31,283 shares of the company’s stock in a transaction dated Monday, June 29th. The stock was sold at an average price of $109.48, for a total value of $3,424,862.84. Following the completion of the sale, the director owned 461,794 shares of the company’s stock, valued at approximately $50,557,207.12. The trade was a 6.34% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 3,587,629 shares of company stock valued at $386,183,782 in the last quarter. Insiders own 15.98% of the company’s stock.

Kymera Therapeutics Stock Performance

Kymera Therapeutics stock opened at $119.05 on Wednesday. Kymera Therapeutics, Inc. has a one year low of $39.84 and a one year high of $130.05. The stock has a fifty day moving average of $113.58 and a 200 day moving average of $94.25. The stock has a market cap of $9.90 billion, a PE ratio of -36.74 and a beta of 1.96.

Kymera Therapeutics (NASDAQ:KYMR) last released its quarterly earnings results on Wednesday, August 5th. The company reported ($0.62) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.71) by $0.09. Kymera Therapeutics had a negative return on equity of 21.22% and a negative net margin of 285.33%.The business had revenue of $65.00 million during the quarter, compared to the consensus estimate of $32.78 million. During the same period in the previous year, the company posted ($0.95) EPS. The business’s quarterly revenue was up 465.2% compared to the same quarter last year. As a group, sell-side analysts predict that Kymera Therapeutics, Inc. will post -3.78 EPS for the current fiscal year.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc is a clinical?stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small?molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease?causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.